---
layout: post
title: New Drug Approvals 2013 - Pt. III - Pomalidomide (PomalystTM)
date: '2013-02-24T19:08:00.000Z'
author: Rita
tags:
- Oral Drugs
- Small Molecule Drugs
- 2013 New Drugs
- Black Box Warning Drugs
modified_time: '2013-07-11T14:38:01.124+01:00'
thumbnail: http://1.bp.blogspot.com/-q_Eu9CqSE9U/USefx9BoanI/AAAAAAAAA3k/7GAuhHsjxS4/s72-c/CHEMBL43452.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-4656923310688887009
blogger_orig_url: http://chembl.blogspot.com/2013/02/new-drug-approvals-2013-pt-iii.html
---

<div class="separator" style="clear: both; text-align: center;"><a href="http://www.celgene.com/products/gallery/Pomalyst.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://www.celgene.com/products/gallery/Pomalyst.jpg" /></a></div><br />
<center face="arial"><img src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,0,0,0,1,0,0,1,1" width="400" /></center><br />
<div style="text-align: center;"><b>ATC Code:</b> <a href="http://www.whocc.no/atc_ddd_index/?code=L04A">L04A</a> (partial)<br />
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Pomalidomide">Pomalidomide</a><br />
<br />
</div><div style="text-align: justify;">On February 8<sup>th</sup>, the FDA approved Pomalidomide (Tradename: <a href="http://www.trademarkia.com/pomalyst-85150878.html">Pomalyst</a>; Research Code: CC-4047, IMiD 3), a <a href="http://en.wikipedia.org/wiki/Thalidomide">thalidomide</a> analogue, indicated for the treatment of <a href="http://en.wikipedia.org/wiki/Multiple_myeloma">multiple myeloma</a> in patients who failed to respond to previous therapies (e.g. <a href="http://en.wikipedia.org/wiki/Lenalidomide">lenalidomide</a> and <a href="http://en.wikipedia.org/wiki/Bortezomib">bortezomib</a>).</div><br />
<div style="text-align: justify;">Multiple myeloma is a form of blood cancer that primarily affects older adults, and arises from the accumulation of abnormal <a href="http://en.wikipedia.org/wiki/Plasma_cell">plasma cells</a> in the bone marrow. These abnormal plasma cells produce large amounts of unneeded antibodies, which are then deposited in various organs, causing renal failure, <a href="http://en.wikipedia.org/wiki/Polyneuropathy">polyneuropathy</a> and other myeloma-associated symptoms.</div><br />
<div style="text-align: justify;">Pomalidomide, an analogue of thalidomide, is an <a href="http://en.wikipedia.org/wiki/Immunotherapy">immunomodulatory agent</a> with antineoplastic activity. Like other thalidomide analogs, the exact mechanism of action is yet not fully understood, however <i>in vitro</i> assays demonstrated that pomalidomide inhibited proliferation and induced <a href="http://en.wikipedia.org/wiki/Apoptosis">apoptosis</a> of hematopoietic tumor cells, including lenalidomide-resistant multiple myeloma cell lines. It has also been shown that pomalidomide enhanced <a href="http://en.wikipedia.org/wiki/T_cell">T cell</a> and <a href="http://en.wikipedia.org/wiki/Natural_killer_cell">natural killer (NK) cell-mediated immunity</a> and inhibited production of pro-inflammatory <a href="http://en.wikipedia.org/wiki/Cytokines">cytokines</a> (e.g., TNF-α and IL-6). For more information take a look at this <a href="http://www.ncbi.nlm.nih.gov/pubmed/23318436">review</a>.</div><br />
<div style="text-align: justify;">Pomalidomide, like other thalidomide derivatives, belongs to the -domide USAN/INN stem. Members of this class are thalidomide, lenalidomide (both approved drugs and licensed by Celgene Corporation), and Mitindomide and Endomide. Pomalidomide is a result of a quest for safer analogs of thalidomide, and has a higher potency than any of its predecessors. </div><br />
<div class="separator" style="clear: both; text-align: center;"><a href="http://1.bp.blogspot.com/-q_Eu9CqSE9U/USefx9BoanI/AAAAAAAAA3k/7GAuhHsjxS4/s1600/CHEMBL43452.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-q_Eu9CqSE9U/USefx9BoanI/AAAAAAAAA3k/7GAuhHsjxS4/s320/CHEMBL43452.png" /></a></div><br />
<div style="text-align: justify;">Pomalidomide (IUPAC Name: 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione; Canonical smiles: Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 ; ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL43452">CHEMBL43452</a>; PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=134780">134780</a>; ChemSpider: <a href="https://www.chemspider.com/Chemical-Structure.118785.html">118785</a>; Standard InChI Key: UVSMNLNDYGZFPF-UHFFFAOYSA-N) is a derivative of thalidomide, with a molecular weight of 273.2 Da, 5 hydrogen bond acceptors, 2 hydrogen bond donors, and has an ALogP of -0.65. The compound is therefore fully compliant with the rule of five.</div><br />
<div style="text-align: justify;">Pomalidomide is available in the capsular form, and the recommended daily dose is 4 mg on days 1-21 of repeated 28-day cycles until disease progression. Following administration of single oral doses in patients with multiple mieloma, the systematic exposure was characterized by an AUC(Τ) of 400 ng.hr/ mL and maximum plasma concentration (C<sub>max</sub>) of 75 ng/mL. At steady state, the mean apparent volume of distribution (Vd/F) was 62-138 L. Pomalidomide is weakly bound to human plasma proteins (12-44%). <br />
<br />
Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4, with additional minor contributions from CYP2C19 and CYP2D6. Pomalidomide is also a substrate for P-glycoprotein (P-gp). The elimination median plasma half-life (t<sub>1/2</sub>) for pomalidomide is approximately 9.5 hours in healthy subjects and 7.5 in patients with multiple mieloma. Pomalidomide has a mean total body clearance (CL/ F) of 7-10 L/hr. </div><br />
<div style="text-align: justify;">Pomalidomide has been issued with a black box warning due to its teratogenic profile, i.e., it can cause severe life-threatening birth defects, and also due to its higher risk for venous thromboembolism in patients exposed to the drug. Because of Pomalyst’s embryo-fetal risk, it is available only through the Pomalyst Risk Evaluation and Mitigation Strategy (REMS) Program. </div><br />
<div style="text-align: justify;">The license holder for Pomalyst<sup>TM</sup> is <a href="http://www.celgene.com/">Celgene Corporation</a>, and the full prescribing information can be found <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf">here</a>.</div>